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A B S T R A C T
Background: Pulmonary nocardiosis (PN) is an uncommon but potentially life-threatening infection. Mostof
ourknowledge on PNis derived fromcase reports andsmallcase series. Increasing incidence ratesof PNhave
been reported recently. The aim of this study was to describe the clinical course of and risk factors for PN in
four Western European countries and to estimate population-based annual hospitalization rates.
Methods: This was a retrospective evaluation (1995–2011) of the clinical course of and risk factors for PN in
patients at 11 hospitals in four European countries (Germany, Austria, Switzerland, and the Netherlands).
Population-based estimates of hospitalization rates for PN in Germany (2005 to 2011) were calculated
using ofﬁcial German nationwide diagnosis-related groups (DRG) hospital statistics.
Results: Forty-three patients fulﬁlled stringentcriteria for proven (n = 8) and probable (n = 35) PN; seven had
extrapulmonary dissemination. For these 43 patients, the major risk factors for PN were immunocom-
promising (83.7%) and/or pulmonary (58.1%; as only comorbidity in 27.9%) comorbidities. The median
duration of PN targeted therapy was 12 weeks. Distinctive patterns of resistance were observed (imipenem
susceptibility: Nocardia farcinica 33.3%; Nocardia asteroides 66.7%). The overall mortality rate was 18.9%
(50% in disseminated PN). Over time, annual PN hospitalization rates remained unchanged at around 0.04/
100 000, with the highest rate among men aged 75–84 years (0.24/100 000).
Conclusions: PN is a rare, but potentially life-threatening disease, and mainlyaffects immunocompromised
elderly males. Overall, annual hospitalization rates remained stable between 2005 and 2011.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Nocardiosis is a rare infection caused by Nocardia spp.
Nocardiaceae are aerobic, Gram-positive, branching, partially
acid-fast ﬁlamentary bacteria that are found worldwide in soil,
decomposing vegetation, dust, and in fresh as well as salt water
(Brown-Elliott et al., 2006). More than 60 different species have
been identiﬁed and half of them have been described as
pathogens in humans (Martinez et al., 2008). Despite their
ubiquitous occurrence, Nocardia spp. are considered to be neither
a commensal of the normal human ﬂora nor a common
laboratory contaminant (McNeil and Brown, 1994). Isolation of
Nocardia spp. from lower respiratory tract samples in the presence
of clinical signs and symptoms of a lower respiratory tract
infection or compatible radiographic ﬁndings should always raise
suspicion of a causative role for this pathogen. Pulmonary
nocardiosis (PN) may have a potentially life-threatening course,
especially in disseminated cases (Hardak et al., 2012; Beaman
et al., 1976; Boiron et al., 1992; Minero et al., 2009). So far,
transmission from human to human has not been documented,
and dissemination usually results from a pulmonary focus
(Ambrosioni et al., 2010).
Nocardiosis mainly manifests as an opportunistic infection in
immunocompromised patients (Chen et al., 2013). An impairment of
cell-mediated immunity is considered to be the major risk factor
(Tremblay et al., 2011; Deem et al., 1983; Beaman and Beaman, 1994;
Filice and Niewoehner,1987). Taking into account the increasing use of
immunosuppressive therapies, including new treatments such as
biological medicines, e.g. monoclonal antibodies, the incidence of
Nocardia infection seems to be on the rise (Minero et al., 2009;
Tremblay et al., 2011). However, reports of immunocompetent
patients with nocardiosis are also emerging (Wilson, 2012). In these
patients, pulmonary comorbidities, mainly chronic obstructive
pulmonary disease (COPD), are important risk factors for PN
(Martinez et al., 2008).
The aims of this study were (1) to characterize the risk factors,
microbiology, and clinical course of PN in a well-deﬁned cohort of
patients in four Western European countries, and (2) to estimate
population-based age- and sex-speciﬁc, as well as age-adjusted
hospitalization rates for PN in Germany.
Materials and methods
Cohort study
This retrospective multicentre study included patients from 11
hospitals in four countries (Germany (n = 7), Austria (n = 2),
Switzerland (n = 1), the Netherlands (n = 1)); the patients were
diagnosed with PN between January 1, 1995 and December 31,2011. A search of the microbiological laboratory data at each
institution was performed to identify eligible patients. Data were
collected from the patient medical records, including demographic
characteristics, clinical signs and symptoms, radiological abnor-
malities on chest X-ray or computed tomography (CT) scans,
laboratory results, microbiological ﬁndings, comorbidities and risk
factors, underlying pulmonary morbidities, immunosuppressive
medications, antibiotic treatment, and outcome.
Case deﬁnition
Only patients with a proven or probable pulmonary Nocardia
infection were included. Due to clinical similarities to fungal
infections, proven and probable PN were deﬁned according to the
European Organisation for Research and Treatment of Cancer
(EORTC) criteria for invasive aspergillosis. Patients had to fulﬁl one
of the following conditions for study entry:
(1) Proven PN: a positive culture from samples taken from a sterile
primary site, e.g. pleural effusion, blood, Cerebrospinal ﬂuid,
tissue biopsy, or abscess puncture AND (i) radiological ﬁndings
on chest X-ray or CT scan of the thorax compatible with
pulmonary nocardiosis OR (ii) clinical signs and symptoms of a
lower respiratory tract infection (cough, sputum, dyspnoea,
fever >38.3 C).
(2) Probable PN (one of the following): (i) a positive culture from
sputum, tracheobronchial aspirate, or bronchoalveolar lavage
(BAL) AND (a) clinical signs and symptoms of a lower
respiratory tract infection (cough, sputum, dyspnoea, fever
>38.3 C) AND (b) radiological ﬁndings on chest X-ray or CT
scan of the thorax consistent with pulmonary nocardiosis; (ii)
microscopic proof of Gram-positive, branching, partially acid-
fast ﬁlamentary bacteria in histological samples (identiﬁed as
Nocardia spp.) AND (a) clinical signs and symptoms of a lower
respiratory tract infection (cough, sputum, dyspnoea, fever
>38.3 C) OR (b) radiological ﬁndings on chest X-ray or CT scan
of the thorax consistent with pulmonary nocardiosis.
Patients with proven and probable PN were then included as a
single cohort and their data summarized and analyzed. Patients
under the age of 18 years were excluded from this study.
Microbiology
At all institutions, the identiﬁcation of Nocardia spp. and
susceptibility testing were performed only upon special request.
Since genotypic methods for species identiﬁcation as part of
clinical routine (e.g.,16S rRNA gene PCR) became available only late
during the study period, patients with conventional phenotypic
and biochemical species identiﬁcation were included, as well as
patients with genotypic identiﬁcation results.
Table 1
Demographic and epidemiological characteristics of 43 patients with pulmonary
nocardiosis.a
Age (years), mean  SD (range) 55.8  14.4
(21–75)
Sex
Male 31/43 (72.1%)
Female 12/43 (27.8%)
Admission diagnosis (n = 38)
Pneumonia 21/38 (55.3%)
Lung cancer/metastasis 3/38 (7.9%)
Tuberculosis 2/38 (5.3%)
Acute exacerbation of a pre-existing lung disease (e.g.
bronchiectasis, COPD)
2/38 (5.3%)
Pleural effusion/empyema 2/38 (5.3%)
Pulmonary nocardiosis 2/38 (5.3%)
Otherb 6/38 (15.8%)
Antibiotic pretreatment 24/43 (55.8%)
Underlying diseasec 40/43 (93.0%)
Pulmonary morbidityc 25/43 (58.1%)
COPD 8/43 (18.6%)
Tuberculosis 5/43 (11.6%)
Bronchiectasis 3/43 (7.0%)
Interstitial lung disease 4/43 (9.3%)
Other pulmonary diseased 10/43 (23.3%)
Solid organ transplantation 11/43 (25.6%)
Haematological disease 10/43 (23.3%)
Diabetes mellitus 6/43 (14.0%)
Autoimmune disease 5/43 (11.6%)
Liver disease 2/43 (4.7%)
Severe renal impairment 2/43 (4.7%)
Immunosuppressive therapy 22/43 (51.2%)
Combination therapy 14/43 (32.6%)
Monotherapy (corticosteroid) 8/43 (18.6%)
COPD, chronic obstructive pulmonary disease; CMV, cytomegalovirus; SD, standard
deviation.
a Results are presented as the number and percentage (%), unless speciﬁed
otherwise.
b One patient each with one of the following: haemoptysis, fever of unknown
origin, meningitis, vertigo and nausea, rejection following lung transplantation,
cryptogenic organizing pneumonia.
c Patients could have more than one underlying disease or pulmonary morbidity.
d One patient each with: asthma, cystic ﬁbrosis, chronic pulmonary CMV
infection, obstructive sleep apnoea, pulmonary aspergillosis, non-tuberculous
mycobacteria infection, primary ciliary dyskinesia, pulmonary p-ANCA vasculitis,
chronic bronchitis.
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A disseminated course was deﬁned as proven or probable PN
with involvement of at least one other non-contiguous organ, or a
radiological ﬁnding, e.g. abscess formation in organs other than the
lungs, such as the brain or abdomen, interpreted as being
compatible with Nocardia infection in a patient with PN.
Immunosuppressive medication was deﬁned as chronic (>4
weeks) intake of steroids at a dosage of >10 mg prednisone or
equivalent per day, or the use of another immunosuppressive
agent such as a calcineurin inhibitor, mycophenolate, cytostatic
agent, mTOR inhibitor, TNF-binding protein, or other biological
medicine.
Estimation of the hospitalization rate in Germany
For the estimation of the annual population-based hospitaliza-
tion rates for PN, the ofﬁcial German nationwide diagnosis-related
groups (DRG) hospital statistics were analyzed (German Federal
Health Monitoring System, 2013). These have included data on
primary discharge diagnoses since inception and on all secondary
discharge diagnoses since 2005, from all German hospitals using
DRG billing of medical services. Almost all German hospitals use
this system, with the exception of hospitals for prevention,
rehabilitation, and mental and mood disorders, and day care
units. Cases were identiﬁed by extracting all records for which the
four-digit International Classiﬁcation of Diseases, 10th revision
(ICD-10) code A43.0 (pulmonary nocardiosis) within the three-
digit category A43 (nocardiosis) was listed as a primary or
secondary hospital discharge diagnosis. De-identiﬁed DRG diag-
nosis data were provided for the whole of Germany as absolute
numbers stratiﬁed by age group, sex, and year of diagnosis.
Statistical analysis
Results are expressed as frequencies or as the mean  standard
deviation (SD) unless indicated otherwise. The two-tailed Fisher’s
exact test was used to compare proportions. The signiﬁcance level
was set to 5% for all analyses, and p-values are reported. All data
were analyzed and processed using IBM SPSS Statistics version
21.0 (IBM Corp., Armonk, NY, USA) on a Windows XP operating
system (Microsoft, Redmond, WA, USA).
For the estimation of PN hospitalization rates, all hospital-
izations with PN as the primary or secondary hospital discharge
diagnosis in Germany from 2005 through 2011 were included.
Ofﬁcial German census age- and sex-speciﬁc population data were
used as the denominator for all calculations (German Federal
Health Monitoring System, 2013). Age adjustment was performed
by direct method in order to control for different age distributions
across Germany and to allow for comparison between different
years. Age-adjusted hospitalization rates were estimated using the
appropriate German Census Standard Population as the reference
population. The data analysis was performed in Excel (Microsoft).
Results
Cohort study
Patients
Fifty-eight patients with microbiologically proven Nocardia spp.
were identiﬁed. Of these, 43 patients fulﬁlled the criteria for
proven (n = 8) or probable (n = 35) PN and were included in the
study. Most patients were recruited in Germany (n = 22), followed
by Austria (n = 13), Switzerland (n = 6), and the Netherlands (n = 2).
Forty patients (93.0%) presented with relevant comorbidities. A
pulmonary comorbidity was the most frequent predisposing factor
(n = 25); this was the only underlying comorbidity in 12/43patients (27.9%). Twenty-two patients (51.2%; n = 22/43) were
receiving immunosuppressive treatment, of whom eight were
receiving corticosteroid monotherapy (see Table 1). HIV testing
was performed for 20 patients and all tested negative. Twenty-four
patients had received antibiotic treatment prior to admission.
Details of the demographic and epidemiological characteristics are
summarized in Table 1.
Clinical and radiological ﬁndings
The clinical picture was non-speciﬁc and comparable to other
entities of lower respiratory tract infection (see Table 2). Due to
incomplete data, information on sputum colour, pleuritic chest
pain, and haemoptysis were not available. Overall, inﬂammatory
parameters were only moderately elevated, despite wide ranges of
values (Table 2). Owing to the non-speciﬁc clinical appearance of
PN, the median time to ﬁnal diagnosis was 14 days (range 0–54
days).
Detailed clinical and/or radiological data on extrapulmonary
involvement were available for 38 patients, and seven patients
(18.4%; n = 7/38) suffered from disseminated nocardiosis (Table 2).
The central nervous system (CNS) was the most frequently affected
site (n = 5). Two patients presented extrapulmonary foci in more
than one additional organ.
Table 2
Clinical signs and symptoms, additional extrapulmonary foci, time from admission
to diagnosis, and laboratory values.
Number %
Clinical signs and symptomsa (n = 43)
Cough 33/43 76.7%
Fever 27/43 62.8%
Sputum 26/43 60.5%
Dyspnoea 17/43 39.5%
Weight loss 7/43 16.3%
Disseminated course, extrapulmonary focia
(n = 38)
7/38 18.5%
Brain 5/38 13.2%
Soft tissue 2/38 5.3%
Skin 1/38 2.6%
Abdomen 1/38 2.6%
Mean  SD Median
(range)
Time from admission to ﬁnal diagnosis (days)
(n = 29)
16.8  13.2 14.0 (0–54)
Inﬂammatory markers on blood examination
(n = 37)
CRP (mg/l) 102.1  104.9 66.0 (0–429)
WBC (109/l) 11.6  8.5 10.5 (2.1–
37.1)
CRP, C-reactive protein; SD, standard deviation; WBC, white blood cell count.
a Patients could have more than one.
Figure 1. Radiological distribution of abnormalitie
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patients. Similar to the clinical picture, radiological ﬁndings were
also variable, non-speciﬁc, and heterogeneous. The most frequent
abnormality was pulmonary airspace consolidation (89.7%; n = 35/
39) with or without air bronchograms, followed by (reticulo)-
nodular changes (30.1%; n = 12/39). Abscess-forming consolida-
tions or cavitations were present in nine patients (23.1%; n = 9/39)
and pleural effusion in four patients (10%; n = 4/39). Details of the
distribution of radiological ﬁndings are presented in Figure 1.
Microbiological ﬁndings
Data on species identiﬁcation were available for 28 patients. A
total of 37 different isolates were identiﬁed (see Figure 2). A single
Nocardia spp. (n = 6) was identiﬁed in most patients; four patients
had two different species, one patient had three different species,
and one patient had four different species. Nocardia farcinica
(n = 8), Nocardia asteroides (n = 7), and Nocardia cyriacigeorgica
(n = 3) accounted for almost 50% of all infections with identiﬁcation
beyond just genus recognition. Data on the duration of growth in
culture were available for 24 patients, and the median time to
growth was 16 days (mean 18.2  14.7 days; range 2–58 days).
Specimens obtained by bronchoscopy such as BAL, trans-
bronchial lung biopsy, and tracheobronchial aspirate were
diagnostic in 27 patients, indicating that endoscopic procedures
were performed in approximately two-thirds of all patients
(Table 3). Nineteen additional microorganisms were recovered
from 16 patients (37.2%; n = 16/43) (Table 3).s in 39 patients with pulmonary nocardiosis.
Figure 2. Distribution of Nocardia spp. (n = 37).
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isolates from six different species (Table 4).
Treatment and outcome
All patients received antibiotic therapy, and a variety of
antibacterial agents were given (see Table 5). Orally and
intravenously applied trimethoprim–sulfamethoxazole (TMP–
SMX; 15 mg/kg of the trimethoprim component per day) was
the most frequently prescribed treatment, either as initial therapy
or as sequential oral treatment following parenteral ‘induction’
therapy with imipenem with or without amikacin. Most patients
received antibiotic therapy for a prolonged period of time (median
12 weeks; range 1–52 weeks).
Six patients were lost to follow-up, most frequently due to
transfer to other medical institutions. The overall mortality rate
was 18.9% (n = 7/37) and a trend towards higher mortality inTable 3
Microbiological results: source of clinical specimen and presence of co-infections
(n = 43).
Number %
Type of diagnostic specimen
BAL 19/43 44.2%
Sputum 9/43 20.9%
Tracheobronchial aspirate 5/43 11.6%
Lung biopsy 3/43 7.0%
Brain abscess 3/43 7.0%
Skin and soft tissue abscess 2/43 4.7%
Pleural effusion 2/43 4.7%
Pulmonary co-infectiona 16/43 37.2%
CMV 3/16 18.8%
Staphylococcus aureus 2/16 12.5%
Pseudomonas aeruginosa 2/16 12.5%
MTB 2/16 12.5%
NTM 2/16 12.5%
Aspergillus spp. 2/16 12.5%
Otherb 6/16 37.5%
BAL, bronchoalveolar lavage; CMV, cytomegalovirus; MTB, Mycobacterium tubercu-
losis; NTM, non-tuberculous mycobacteria; SD, standard deviation.
a Patients could have more than one.
b One patient each with one of the following: Moraxella spp., Escherichia coli,
Stenotrophomonas maltophilia, Haemophilus parainﬂuenzae, Pneumocystis jirovecii,
Ralstonia pickettii.patients with disseminated nocardiosis was observed (50% vs.
15.4%; p = 0.101), with the highest mortality rate in patients with
CNS involvement (75%); all patients with a fatal disseminated
infection had CNS involvement.
Population-based estimates of annual rates of hospitalized PN in
Germany between 2005 and 2011
From 2005 to 2011, the average annual German population was
82.1 million (range 81.1–82.4 million). During this period, an
average 1673 hospitals (95% conﬁdence interval (CI) 1633–1719)
were subject to DRG billing of medical services and the average
overall number of hospitals in Germany was 2087 (95% CI 2067–
2108). Therefore, 80% of all hospitals were covered by the study
analysis. A total of 125.2 million hospitalizations were analyzed for
the period 2005–2011 (an average 17.9 (95% CI 17.4–18.3) million
hospitalizations per year) over an observation period of 574.4
million person-years. Overall, 266 hospitalizations with PN as
either the primary or secondary diagnosis were identiﬁed. The
overall average annual age-adjusted hospitalization rate was 0.04
per 100 000 inhabitants: 0.05 per 100 000 in males and 0.03 per
100 000 in females. However, there was considerable variation
with age, with the highest age-speciﬁc hospitalization rate of 0.24/
100 000 inhabitants among men aged 75–84 years (Figure 3A).
During the study period, the annual number of PN-associated
hospitalizations remained relatively unchanged between 2005 and
2011 for both males and females (Figure 3B).
Discussion
This study investigated a large cohort of PN patients in
European countries, applying a stringent deﬁnition of PN. It
therefore provides important insights into the epidemiology and
clinical appearance and course of this rare infection in high-
income countries.
The pivotal role of immunocompromising comorbidities and
treatments as major risk factors for PN has been described
previously (Martinez et al., 2008; Minero et al., 2009; Ambrosioni
et al., 2010; Chen et al., 2013; Poonyagariyagorn et al., 2008;
Takiguchi et al., 2017). In the present study cohort, 93% of all
patients were suffering from a relevant comorbidity and 51.2%
Table 4
Results of susceptibility testing.a
Susceptibility
TMP–SMX Amikacin Imipenem Benzylpenicillin Piperacillin
Nocardia spp. (n = 4) 100% (4) 100% (4) 100% (4) 75% (3) 100% (4)
Nocardia abscessus (n = 4) 75% (3) 100% (4) 50% (2) 75% (3) 75% (3)
Nocardia asteroides (n = 3) 100% (3) 100% (3) 66.7% (2) 100% (3) 100% (3)
Nocardia farcinica (n = 3) 100% (3) 100% (3) 33.3% (1) 100% (3) 100% (3)
Nocardia cyriacigeorgica (n = 2) 100% (2) 100% (2) 100% (2) 100% (2) 100% (2)
Nocardia veterana (n = 3) 100% (3) 100% (3) 100% (3) 66.7% (2) 100% (3)
Nocardia otitidiscaviarum (n = 1) 100% (1) 100% (1) 100% (1) 100% (1) 100% (1)
Total (n = 20) 95% (19) 100% (20) 75% (15) 85% (17) 95% (19)
TMP–SMX: trimethoprim–sulfamethoxazole.
a Breakpoints for resistance are those of the Clinical and Laboratory Standards Institute (CLSI), version M24 A2 (2011).
Table 5
Antibiotic treatment of 43 patients with pulmonary nocardiosis.
Number %
Antibioticsa
TMP–SMX 22 51.2%
Carbapenem 18 41.9%
Amikacin 12 27.9%
Cephalosporin 8 18.6%
Penicillin 8 18.6%
Quinolone 5 11.6%
Tetracycline 4 9.3%
Linezolid 4 9.3%
Macrolide 3 7.0%
Otherb 8 18.6%
Mean  SD Median (range)
Duration of treatment (weeks) (n = 37) 15.6  14.9 12 (1–52)
SD, standard deviation; TMP–SMX, trimethoprim–sulfamethoxazole.
a Patients could have more than one.
b Standard anti-tuberculous treatment (n = 4), glycopeptide (n = 2), sulfadiazine
(n = 1), clindamycin (n = 1).
Figure 3. Population-based estimates of annual incidence rates of hospitalized
cases with pulmonary nocardiosis: (A) average annual age-speciﬁc hospitalization
rate; (B) annual age-adjusted incidence rates of hospitalized pulmonary nocardiosis
in Germany from 2005 to 2011.
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patients were receiving a combination of various immunosup-
pressive agents, although eight patients were being treated with
only systemic corticosteroid monotherapy. Single organ trans-
plantation (SOT) was the most common risk factor in this cohort.
This conﬁrms the data from most recent reports, showing the
occurrence of PN in 1.3% to 3.5% of all SOT recipients (Poonyagar-
iyagorn et al., 2008; Peleg et al., 2007; Hemmersbach-Miller et al.,
2018; Majeed et al., 2018).
PN may also occur in immunocompetent patients, mainly those
with a pulmonary comorbidity, especially COPD (Chen et al., 2013;
Hui et al., 2003; Chen et al., 2014; Kurahara et al., 2014; Martinez
Tomas et al., 2007). Impaired ciliary motility and epithelial damage
lead to impaired local immune defence, and systemic corticoste-
roids may promote nocardial infection (Elenkov, 2004). Over half of
the patients (58.1%) had an underlying pulmonary comorbidity,
most commonly COPD (this was the sole comorbidity in 12
patients). Pulmonary comorbidity, particularly COPD and bronchi-
ectasis, has been described as a risk factor for PN in non-
immunosuppressed patients (Woodworth et al., 2017; Steinbrink
et al., 2018).
Recent reports addressing radiological abnormalities in PN
agree that the alterations found in PN are diverse, not pathogno-
monic, and may mimic a multitude of pulmonary diseases (Chen
et al., 2014; Kurahara et al., 2014; Blackmon et al., 2011; Tsujimoto
et al., 2012). Despite the non-discriminative and non-speciﬁc
radiographic picture of PN, this study is novel in demonstrating
that PN predominantly affects the right upper lobe, even after the
exclusion of co-infected patients from the analyses. However, this
contradicts the ﬁndings of previous studies, which have shown noparticular distribution of radiographic abnormalities or even a
lower lobe predominance (Chen et al., 2014; Blackmon et al., 2011;
Tsujimoto et al., 2012). A possible explanation could be the
stringent deﬁnition of PN applied in the present study, ensuring
the inclusion of ‘true’ PN only. Furthermore, the aerobic nature of
Nocardia spp. and the fact that the right upper lobe is regarded as
one of the best ventilated areas of the lungs may potentially
explain the greater upper lobe involvement.
Due to the non-speciﬁc clinical and radiological presentation, a
delay between the onset of symptoms and a deﬁnitive PN diagnosis
is common, and PN is initially often misdiagnosed. The diagnostic
delay of 14 days in the study cohort is in line with the recent
literature, reporting mean diagnostic intervals of 13.6 to 42 days
(Poonyagariyagorn et al., 2008; Martinez Tomas et al., 2007). The
diagnostic delay may also be attributed to the delayed growth in
culture, which may take up to 3 weeks (Ambrosioni et al., 2010;
Ashdown, 1990). Therefore, the microbiology laboratory should
always be contacted when a nocardial infection is suspected to
ensure that the corresponding specimens are incubated for a
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molecular techniques for the detection of the organism (Ambro-
sioni et al., 2010).
In this cohort, 18.4% of all evaluable patients had a
disseminated infection, mainly with CNS involvement. However,
evaluable cerebral CT scans were available for only 12 patients;
therefore, the true incidence of this disseminated course is
possibly underestimated. An active search for dissemination,
including cerebral CT scan or magnetic resonance imaging and
ophthalmological investigations (uveitis), is of particular
importance, because dissemination  is directly linked to the
outcome and the selection of deﬁnitive antibiotic therapy (CNS
penetration) (Ambrosioni et al., 2010; Corti and Villafane-Fioti,
2003).
The most commonly used antibiotics were TMP–SMX,
imipenem, amikacin, and ceftriaxone, which are all generally
recommended as initial treatment for PN (Brown-Elliott et al.,
2006; Wilson, 2012). In most patients, a treatment duration of 6
months is considered sufﬁcient, whereas in cases with CNS
involvement or in severely immunosuppressed cases, even more
prolonged treatment may be necessary (Ambrosioni et al., 2010;
Corti and Villafane-Fioti, 2003). However, some authors have
recommended shorter treatment courses (Tripodi et al., 2011).
The results of the present study, with a high clinical cure rate
(overall >80% and almost 90% in non-disseminated cases) and a
median treatment duration of 12 weeks may provide additional
support for future shortening of antibiotic therapy in selected
patients.
Some species presented clinically relevant resistance that may
lead to inadequate treatment and treatment failure. N. farcinica and
N. asteroides, the two most frequent species in this cohort, were
susceptible to imipenem in only 33.3% and 66.7% of cases,
respectively, whereas susceptibility to all other tested antibiotics
was 100%. Of note, amikacin was the only tested drug with proven
in vitro efﬁcacy against all Nocardia abscessus isolates in this
cohort. The study ﬁndings add to the available data on
susceptibility testing and demonstrate increasing resistance to
commonly recommended antibiotics (Minero et al., 2009; Uhde
et al., 2010; Lebeaux et al., 2018; Schlaberg et al., 2014; Valdezate
et al., 2017; McTaggart et al., 2015). In addition, the data are in line
with those of a recent study from France, showing that N. farcinica
is the most common species in human infection in Western
Europe, with a distinct pattern of susceptibility (Lebeaux et al.,
2018). Early species identiﬁcation using 16sRNA PCR sequencing or
multilocus sequencing typing and susceptibility testing may help
to improve antibiotic treatment, although the clinical impact of the
observed resistance remains unclear.
In contrast to earlier case series and recent epidemiological
studies based on laboratory testing only, a major strength of the
present study is the clear and restrictive deﬁnition of PN, making
the unintended inclusion of cases with colonization improbable.
Although Nocardia spp. are neither commensals of the normal
human ﬂora nor common laboratory contaminants, the sole
detection of Nocardia spp. in respiratory samples, especially
sputum, in the absence of clinical or radiological signs and
symptoms, does not necessarily represent an infection in progress.
Another strength of this study is the fact that patients from an
unselected cohort were included (all patients from the participat-
ing institutions) rather than searching for cases in selected
populations such as HIV-positive patients or SOT and bone marrow
transplant recipients. The data therefore reﬂect the complete
clinical, microbiological, and radiographic spectrum of PN that
may be encountered in general medical departments and
pulmonology divisions.
This was a retrospective evaluation with all the limitations
that come with a retrospective study design, especially theproblem of missing data. The identiﬁcation of Nocardia spp. and
susceptibility testing were performed only upon special request.
Therefore, the species distribution may not reﬂect the real
importance of each species in PN. The numbers of patients per
country varied considerably, making comparison between coun-
tries impossible. However, since all four countries provide
comparable standards of medical care in terms of diagnostic
facilities, availability of therapies and medical procedures, and
prevalence of comorbidities considered as typical risk factors for
nocardiosis, it is believed that the pooled data may be
representative of Western European countries, although not
generally transferable to other countries.
The population-based estimate of the hospitalization rate
(0.04/100 000 inhabitants) may serve as a surrogate for annual
incidence and is considerably lower than rates reported
previously: 0.39–0.55/100 000 inhabitants in Spain (0.20 if
extrapolated to the whole population of Spain) and 0.33–0.87/
100 000 inhabitants in Canada (Minero et al., 2009; Tremblay
et al., 2011). There may be important reasons for this difference.
The present study focused on pulmonary nocardiosis only,
whereas the other cohorts included nocardiosis independent of
the site of infection. Furthermore, in both previous studies, cases
were identiﬁed by microbiological proof of Nocardia spp., without
differentiating between infection and colonization. In contrast, the
present study estimates are based on the coding of hospital
discharge diagnoses for billing (ICD-10 codes), making coloniza-
tion unlikely, because diagnostic and therapeutic efforts have to be
justiﬁed for reimbursement and medical charts are frequently
reviewed by health insurance companies. However, they are
considered to have high speciﬁcity, but only moderate sensitivity,
thus being prone to an underestimation of disease prevalence
(O’Malley et al., 2005).
The study estimates are the ﬁrst to be based on a representative
nationwide population-based analysis, including 80% of all
hospitals across Germany and >125 million hospitalizations over
a 7-year period. Therefore, a possible bias due to differences in PN-
associated hospitalizations in rural and urban areas, mainly due to
potential regional differences in health care utilization, can be
excluded. However, it was not possible to account for readmis-
sions. Finally, the results apply to hospitalized populations only. PN
is often a chronic infection and usually requires long-term follow-
up care in the outpatient setting, where disease prevalence is
presumably different. Therefore, the data are likely to underesti-
mate the overall burden of PN. However, as available data are
limited, the results are the best currently available surrogate for
the epidemiological trends of PN across a large Western European
country (Germany).
In contrast to the Canadian and the Spanish cohorts, no trend
towards an increasing incidence over time was observed in this
study. This previously described trend was explained by an
increasing number of immunocompromised and immunosenes-
cent patients in developed countries, improved laboratory
detection techniques, and an increased awareness of PN in
patients at risk during the observation periods (Minero et al.,
2009; Tremblay et al., 2011; Agterof et al., 2007). The discrepancy
between the present study and previous studies might be
explained by differences in the observation period. Minero
et al. evaluated incidences between 1995 and 2006 and Tremblay
et al. between 1988 and 2008, whereas this study analyzed the
period between 2005 and 2011 (Minero et al., 2009; Tremblay
et al., 2011). Therefore, immunosuppressive treatment with
biological medicines, which was introduced in the early 2000s,
as well as genotypic methods for species identiﬁcation were
already in widespread use during the study period and,
furthermore, the number of SOT performed annually did not
increase signiﬁcantly during the study period, in contrast to the
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statistics/data.html).
The epidemiological data conﬁrmed the highest incidence rate
of PN in elderly males, which has previously been assumed from
case series and case reports (Figure 1A) (Minero et al., 2009;
Kurahara et al., 2014). For the ﬁrst time, a discrete female
predominance was observed among younger adults. This might be
attributable to the female predominance in most autoimmune
connective tissue disorders with subsequent immunosuppressive
treatment. However, the data are not sufﬁcient to draw deﬁnitive
conclusions and further studies are needed to establish this as a
distinct phenotype of PN patients.
In conclusion, this study shows that PN remains a rare
pulmonary infection that primarily affects immunocompromised
patients. Between 2005 and 2011, the PN-associated hospitaliza-
tion rates remained unchanged. The clinical appearance is non-
speciﬁc; heightened awareness and clinical suspicion are of
particular importance in patients at risk. Dissemination to
extrapulmonary organs, especially to the CNS, is frequent and
associated with a worse outcome. Cerebral imaging should be
prompted in all patients once the diagnosis of pulmonary
nocardiosis is settled. Different Nocardia spp. may exhibit
distinctive patterns of resistance, making identiﬁcation of Nocardia
spp. beyond just recognition of the genus indispensable. Therefore,
timely prescription of empiric combination therapy may be
beneﬁcial until the results of susceptibility testing are available.
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